|
Radiation Therapy in Treating Patients With Glioblastoma Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Radiation Therapy in Treating Patients With Glioblastoma conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Radiation Therapy in Treating Patients With Glioblastoma Clinical research trials and Radiation Therapy in Treating Patients With Glioblastoma medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Radiation Therapy in Treating Patients With Glioblastoma. Radiation Therapy in Treating Patients With Glioblastoma Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Radiation Therapy in Treating Patients With Glioblastoma clinical trial. Subjects typically recieve the finest healthcare available for their Radiation Therapy in Treating Patients With Glioblastoma condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Radiation Therapy in Treating Patients With Glioblastoma  Radiation Therapy in Treating Patients With Glioblastoma
Radiation Therapy in Treating Patients With Glioblastoma
For Condition: adult glioblastoma multiforme
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pentoxifylline and hydroxyurea may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase I trial to study the effectiveness of radiation therapy plus pentoxifylline and hydroxyurea in treating patients who have high-grade astrocytoma or glioblastoma.
Details: OBJECTIVES: I. Determine the maximum tolerated dose of pentoxifylline administered with hydroxyurea during a course of cranial radiotherapy in patients with glioblastoma multiforme. II. Determine the toxicity of this regimen in these patients. III. Measure PTX levels in plasma and CSF in order to assess whether therapeutic drug exposures (e.g., 0.4-2.0 mM/24 hours) can be achieved with an acceptable level of toxicity. IV. Assess the local control of glioblastoma in patients treated with this regimen. V. Determine the response of surrounding normal brain in patients treated with this regimen. VI. Determine the survival of patients treated with this regimen. PROTOCOL OUTLINE: This is a dose escalation study of pentoxifylline (PTX). Patients receive hydroxyurea (HU) and PTX IV continuously 5 days a week concurrently with cranial radiotherapy twice daily, 5 days a week, for 4 weeks in the absence of disease progression or unacceptable toxicity. The first cohort of 3 patients is treated with radiotherapy and HU alone. Subsequent cohorts of 3-6 patients receive HU and radiotherapy plus escalating doses of PTX until the maximum tolerated dose of PTX is determined or serum or CSF drug concentrations reach 0.4-2.0 mM in 6 consecutive patients with acceptable toxicity. The MTD is defined as the dose immediately preceding that at which 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 1 week, at 1 and 3 months, every 3 months for 2 years, and then every 4 months for 5 years. PROJECTED ACCRUAL: A maximum of 24-34 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven grade IV astrocytoma or glioblastoma multiforme confined to 1 or both hemispheres of the brain; Confirmation of histology by NIH neuropathology review required; MRI or CT completed within 3 weeks of initial evaluation - No clinically apparent leptomeningeal metastases - No uncontrolled seizures despite standard anticonvulsant therapy - No history of epilepsy diagnosed a year or more before glioblastoma --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No prior chemotherapy - Endocrine therapy: Not specified - Radiotherapy: No prior radiotherapy - Surgery: Prior biopsy or subtotal or near-total resection allowed; At least 7-10 days but no more than 3 months since prior surgery and/or biopsy - Other: No recent methylxanthine-containing medications; No concurrent anticoagulants or methylxanthines (e.g., aspirin, nonsteroidal antiinflammatory drugs, warfarin, heparin, theophylline, aminophylline, theobromine) for preexisting medical conditions --Patient Characteristics-- - Age: Over 18 - Performance status: Karnofsky 80-100% OR ECOG 0-1 - Life expectancy: More than 3 months - Hematopoietic: WBC at least 3,500/mm3; Absolute granulocyte count at least 900/mm3; Platelet count at least 100,000/mm3; Hemoglobin at least 10 g/dL; No hematologic disease requiring treatment - Hepatic: Liver function tests no greater than 2.5 times upper limit of normal; No hepatic disease requiring treatment - Renal: Creatinine no greater than 1.3 mg/dL OR Creatinine clearance at least 95 mL/min; No renal disease requiring treatment - Cardiovascular: No history of hospitalization or medication for: Cardiovascular disease with LVEF 45% or less; Myocardial infarction; Arrhythmia Coronary artery disease; Angina; Congestive heart failure; Stroke; No thromboembolic disease requiring treatment - Pulmonary: No history of hospitalization or medication for chronic obstructive pulmonary disease or asthma - Other: No peptic ulcer disease or inflammatory bowel disease within the past 2 years; No documented history of intolerance to methylxanthines (e.g., allergic or serious adverse reactions); No history of psychiatric or medical illness that would preclude therapy; No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix; No contraindication to serial CT or MRI (e.g., logistical problems, noncompliance, contrast allergies); Not pregnant or nursing; Negative pregnancy test
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BrianFuller, Study Chair, National Cancer Institute (NCI)
Radiation Oncology Branch
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: CDR0000064077; NCI-95-C-0069A,NCI-95-C-0069,NCI-95-C-0069D
Study Start Date: April 1995
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00019058
Other Adult Glioblastoma Multiforme Studies:
1. Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
2. Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
3. Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
4. CCI-779 in Treating Patients With Malignant Glioma
5. Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme
Related Studies:
Other adult glioblastoma multiforme Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Radiation Therapy in Treating Patients With Glioblastoma
|
|
|
|
|
|
|
|
